Rebiotix
Rebiotix is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Rebiotix.
Rebiotix is a company.
Key people at Rebiotix.
Key people at Rebiotix.
Rebiotix is a biotechnology company specializing in microbiome-based therapies to treat challenging diseases, particularly recurrent *Clostridium difficile* (C. diff) infections, by restoring the human gut microbiome using its proprietary Microbiota Restoration Therapy (MRT™) platform.[1][2][3] The company develops investigational drugs like RBX2660, a non-antibiotic therapy in late-stage (Phase 3) clinical trials that has received FDA Fast Track, Breakthrough Therapy, and Orphan Drug designations, targeting patients with recurrent C. diff, inflammatory bowel disease, and other microbiome-related conditions.[2][3][5] Acquired by Ferring Pharmaceuticals, Rebiotix serves healthcare providers and patients facing antibiotic-resistant infections, addressing the urgent need for non-antibiotic solutions amid rising C. diff mortality (nearly 30,000 US deaths annually).[3][5] Its growth momentum includes completing enrollment in the first-ever pivotal Phase 3 microbiome trial (over 300 patients) and positive preliminary data, positioning it as a pioneer in standardized, ready-to-use live microbe therapies.[3][5][6]
Rebiotix was founded in 2011 by Lee A. Jones (CEO), Michael Berman, and Erwin A. Kelen in Roseville, Minnesota, with a mission to harness the human microbiome for treating complex diseases, starting with C. diff as an urgent threat.[1][3][5] The idea emerged from recognizing antibiotics' role in disrupting the microbiome and causing recurrences, prompting development of the MRT™ platform to deliver diverse, live human-derived microbes for restoration.[2][3] Early traction built through a deep clinical pipeline, culminating in FDA designations for RBX2660 and its 2018 acquisition by Ferring Pharmaceuticals, which amplified resources for global development.[2][5] Pivotal moments include positive Phase 3 preliminary data (world's first for a microbiome therapy) and trial enrollment completion in 2020.[3][5]
Rebiotix stands out in the microbiome field through these key strengths:
Rebiotix rides the microbiome therapeutics wave, a frontier in biotech shifting from antibiotics to live biotherapeutics amid rising antimicrobial resistance and C. diff's status as a CDC "urgent threat."[3][5] Timing aligns with growing recognition of the gut microbiome's role in diseases (e.g., 10-15% of European hospital infections are recurrent C. diff), fueled by advances in culturing, AI design, and delivery tech.[3][4] Market forces like FDA incentives and demand for non-antibiotic options favor it, with Rebiotix influencing the ecosystem by validating MRT™ as a scalable model—proven in the largest randomized Phase 3 microbiome trial—and partnering for broader applications like maternal health.[4][5] As part of Ferring, it accelerates industry adoption of microbiome drugs, potentially transforming gastroenterology and beyond.[2][6]
Rebiotix is poised for regulatory milestones, with Phase 3 RBX2660 data supporting FDA submission soon after 2020 enrollment and positive results, potentially yielding the first approved microbiome therapy.[3][5][6] Trends like AI-driven consortia and expansions into women's health (via MyBiotics) will shape its path, alongside pipeline maturation for IBD and resistance issues.[4] Its influence may evolve from C. diff pioneer to microbiome platform leader within Ferring, driving paradigm shifts in precision medicine. This builds on its founding vision: revolutionizing treatments through the microbiome's untapped power.[3]
